News & Events

Keep up to date with Isogenica’s latest news on collaborations, Press Releases, Events and VHH antibody resources.


Latest News


Due to their unique characteristics, VHH are promising candidates for a range of application areas including intracellular targeting and even across the Blood Brain Barrier (BBB). Discover all the benefits in using VHH in different applications.

VHH antibodies as biotherapeutics

Camelid heavy-chain only antibodies were discovered in the early 1990’s. Often referred to as VHH antibodies, they are a well characterized alternative to therapeutic IgG’s. Camelid heavy-chain only...

read more



Webinars are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.


Nature Webinar

Register for Isogenica's upcoming webinar Join Isogenica for the upcoming webinar with Nature on 'VHH as building blocks for immune and tumour cell-targeting', presented by Isogenica's CSO Bill...



Catch up with Isogenica’s news and activies through the latest Newsletters.

Creating the next generation of immunotherapies

Immunotherapy has transformed the cancer treatment landscape in recent years, harnessing the power of the immune system to target cancer cells. However, checkpoint inhibitor drugs don’t work for all patients, so the hunt is on for more targeted and personalised therapies that directly engage immune cells with cancer cells.

read more

Isogenica Is Attending Bio Digital 2021

Meet David Mead, Director of Business Development and Associate Director of Marketing, Dr Mandeep Sehmi at the BIO International Convention Digital 2021 June 10-11 & 14-18, to learn the latest developments of VHH single domain antibodies to tumour targets.

read more

Stay Up to Date

Complete the below form to stay up to date with Isogenica’s latest news and events

    By signing up you accept Isogenica's Terms of Use, click here for our privacy policy. You can unsubscribe from Isogenica newsletters at any time using the links in the emails you receive. We use a third party provider, MailChimp, to deliver our newsletter.